Moderna climbs for second straight session

Shares of Moderna MRNA.O rise as much as 9.4% on Monday, last up marginally

Last week, the vaccine maker told Reuters it conducted preclinical research on hantaviruses in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases

Any vaccine will need to demonstrate success in studies likely to cost more than $500 million, funding from governments may help cover these costs - Bernstein analysts

"We don't see this as the next 'pandemic' and think this hantavirus-related trade should fade from current highs ," adds brokerage

Shares of personal protective equipment makers Lakeland Industries LAKE.O rise about 2% and Alpha Pro Tech APT.A gain more than 6%

Including session's moves, MRNA up 84.6% YTD